EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ARF6 Promotes AML Progression via Activation of PI3K / AKT / mTOR Signaling

Haitao Xu iD, Dangui Chen iD, Jia Lu, Long Zhong, Lihong Wang, Jian Ge iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70872 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Haitao Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Leukemia, Myeloid, Acute, ADP-Ribosylation Factors, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute myeloid leukemia (AML) represents a highly aggressive hematological malignancy characterized by a poor prognosis and a pressing demand for innovative diagnostic and prognostic biomarkers. Recent studies have indicated that ADP‐ribosylation factor 6 (ARF6) is overexpressed across various cancer types; however, its specific role and implications in AML have yet to be thoroughly investigated.

Methods

To elucidate the clinical relevance and functional mechanisms of ARF6 in AML, we conducted an integrated analysis utilizing RNA sequencing data from The Cancer Genome Atlas (TCGA) alongside clinical samples and AML cell lines. The diagnostic potential of ARF6 was assessed through receiver operating characteristic curve analysis, and logistic regression was employed to identify factors correlating with elevated ARF6 expression. Functional assays were performed to elucidate the effects of ARF6 modulation on apoptosis, cell cycle progression, and AML cell proliferation, while mechanistic investigations focused on the PI3K/AKT/mTOR signaling pathway, particularly in the context of pharmacological PI3K inhibition.

Results

Our findings revealed a significant upregulation of ARF6 in AML compared to normal controls, with diagnostic efficacy indicated by an AUC of 0.793. Logistic regression analysis identified older age (> 60 years) and a higher white blood cell count (> 20 × 10 9 /L) as significant predictors of high ARF6 expression. Moreover, elevated ARF6 levels were independently associated with shorter overall survival (HR = 1.634, p = 0.045). Notably, ARF6 knockdown induced apoptosis and G0/G1 cell cycle arrest, whereas its overexpression yielded contrary effects. In addition, ARF6 activated the PI3K/AKT/mTOR pathway, which was abrogated by pharmacological PI3K inhibition.

Conclusion

Collectively, our findings establish ARF6 as a valuable diagnostic and prognostic marker in AML, driving disease progression through the activation of the PI3K/AKT/mTOR pathway. These insights not only enhance our understanding of AML pathology but also underscore the potential of targeting ARF6 for therapeutic intervention in AML treatment paradigms. Future research should aim at evaluating the therapeutic implications of targeting ARF6 in combination with existing treatment modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesLeukemia, Myeloid, AcuteADP-Ribosylation FactorsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesHumansADP-Ribosylation Factor 6Signal TransductionDisease ProgressionMaleCell ProliferationFemaleCell Line, TumorMiddle AgedApoptosisPrognosisBiomarkers, TumorAgedAdult

Stichwörter der Autor:innen

AMLARF6PI3K/AKT/mTOR signalingapoptosiscell cycleprognosis

Substanzen

TOR Serine-Threonine KinasesADP-Ribosylation Factor 6ADP-Ribosylation FactorsARF6 protein, humanMTOR protein, humanProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Department of Hematology, Anqing Municipal Hospital, Anqing Medical Center Affiliated to Anhui Medical University, Anqing, Anhui, China.

ORCID-Profile: Haitao Xu, Dangui Chen, Jian Ge

Zitieren

APA

Xu, H., Chen, D., Lu, J., Zhong, L., Wang, L., & Ge, J. (2025). ARF6 Promotes AML Progression via Activation of PI3K / AKT / mTOR Signaling. Cancer Medicine. https://doi.org/10.1002/cam4.70872

Vancouver

Xu H, Chen D, Lu J, Zhong L, Wang L, Ge J. ARF6 Promotes AML Progression via Activation of PI3K / AKT / mTOR Signaling. Cancer Medicine. 2025. doi:10.1002/cam4.70872

BibTeX
@article{Xu2025,
  author = {Xu, Haitao and Chen, Dangui and Lu, Jia and Zhong, Long and Wang, Lihong and Ge, Jian},
  title = {ARF6 Promotes AML Progression via Activation of PI3K / AKT / mTOR Signaling},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70872}
}
Kostenlos starten →